RCKT Rocket Pharmaceuticals, Inc. - Common Stock
$2.98
Price · May 20, 2026
Fundamentals as of May 7, 2026
52W Range
$2–$7
17% of range
Analyst Rating
BUY
20 analysts
Price Target
$9
+212% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
RCKT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.98
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$2 – $7
RCKT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
RCKT
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
RCKT
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
RCKT
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
RCKT
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
RCKT
Peer Median
RCKT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
20 analysts
- Strong Buy 4 20.0%
- Buy 7 35.0%
- Hold 7 35.0%
- Sell 2 10.0%
- Strong Sell 0 0.0%
12-Month Price Target
11 analysts · 2026-05-17
Median
$10.00
← Below all targets
$2.98
Low
$3.00
High
$16.00
Median target
$10.00
+236.1%
Mean target
$9.30
+212.5%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.04%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.42 | $-0.42 | -0.00% |
| Dec. 31, 2025 | $-0.38 | $-0.46 | 0.08% |
| Sept. 30, 2025 | $-0.45 | $-0.52 | 0.07% |
| June 30, 2025 | $-0.59 | $-0.57 | -0.02% |
| March 31, 2025 | $-0.56 | $-0.63 | 0.07% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| RCKT | — | — | — | — | — | — |
| MYGN | $575M | -1.6 | -1.6% | -44.4% | -96.8% | 69.9% |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | — |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
| IMRX | — | -5.2 | — | — | -45.3% | — |
| ORGO | $658M | 34.5 | 17.0% | 6.6% | 13.9% | — |
| PALI | $375M | -7.8 | — | — | -25.4% | — |
| TENX | $114M | -9.1 | — | — | -52.5% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 12
| Metric | Trend | Q1 2026 |
|---|---|---|
| Revenue | $0 | |
| R&D Expense | $31M | |
| SG&A Expense | $17M | |
| Operating Expenses | $49M | |
| Operating Income | $-49M | |
| Interest Expense | $473.0K | |
| Net Income | $-48M | |
| EPS (Basic) | $-0.42 | |
| EPS (Diluted) | $-0.42 | |
| Shares (Basic) | 112,134,059 | |
| Shares (Diluted) | 112,134,059 | |
| EBITDA | $-47M |
Balance Sheet 22
| Metric | Trend | Q1 2026 |
|---|---|---|
| Cash & Equivalents | $50M | |
| Short-term Investments | $95M | |
| Prepaid Expense | $5M | |
| Current Assets | $150M | |
| PP&E (Net) | $27M | |
| PP&E (Gross) | $57M | |
| Accum. Depreciation | $31M | |
| Goodwill | $39M | |
| Intangibles | $25M | |
| Total Assets | $285M | |
| Accounts Payable | $22M | |
| Current Liabilities | $24M | |
| Capital Leases | $2M | |
| Other Non-current Liabilities | $1M | |
| Total Liabilities | $47M | |
| Common Stock | $1M | |
| Paid-in Capital | $1.73B | |
| Retained Earnings | $-1.49B | |
| AOCI | $-112.0K | |
| Stockholders' Equity | $238M | |
| Liabilities + Equity | $285M | |
| Shares Outstanding | 109,123,671 |
Cash Flow 9
| Metric | Trend | Q1 2026 |
|---|---|---|
| D&A | $2M | |
| Stock-based Comp | $8M | |
| Restructuring | $-46.0K | |
| Other Non-cash | $-8M | |
| Operating Cash Flow | $-45M | |
| CapEx | $93.0K | |
| Investing Cash Flow | $17M | |
| Financing Cash Flow | $-1.0K | |
| Free Cash Flow | $-45M |
Profitability 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| ROA | -12.6% | |
| ROE | -14.6% |
Liquidity & Solvency 3
| Metric | Trend | Q1 2026 |
|---|---|---|
| Current Ratio | 6.1 | |
| Quick Ratio | 5.9 | |
| Interest Coverage | -102.6 |
Efficiency 1
| Metric | Trend | Q1 2026 |
|---|---|---|
| Asset Turnover | 0.0 |
Valuation (TTM) 9
| Metric | Trend | Q1 2026 |
|---|---|---|
| Revenue TTM | $0 | |
| Net Income TTM | $-228M | |
| Market Cap | $391M | |
| P/E | -1.7 | |
| P/B | 1.6 | |
| P / Tangible Book | 2.2 | |
| P / Cash Flow | -8.6 | |
| P / FCF | -8.6 | |
| Earnings Yield | -57.3% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.